vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. IBM
5. META
6. MU
7. BLZE
8. PRIM
9. ACN
10. NVDA

Go back to vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes
(NASDAQ: VTVT) Delayed: 35.33 +1.41 (4.16%)
Previous Close $33.92    52 Week High $7.70 
Open $33.96    52 Week Low $4.69 
Day High $35.77    P/E N/A 
Day Low $33.78    EPS $0.00 
Volume 41,753